The Challenges of Orphan Drugs and Orphan Diseases: Real and Imagined | Zendy

Hudson I | Zendy; Breckenridge A | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

The Challenges of Orphan Drugs and Orphan Diseases: Real and Imagined

Author(s) -

Hudson I,

Breckenridge A

Publication year - 2012

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2012.72

Subject(s) - orphan drug , clinical pharmacology , incentive , legislation , pharmacology , medicine , alternative medicine , business , political science , law , economics , bioinformatics , biology , pathology , microeconomics

The Orphan Drug Act of 1983 in the United States and similar legislation in Europe in 1999 provided incentives for companies to develop and sell medicines for diseases with a small market. In this Commentary, we outline the European position on the regulation of orphan drugs and explain where it differs from the regulation in the United States. Clinical Pharmacology & Therapeutics (2012); 92 2, 151–153. doi: 10.1038/clpt.2012.72

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research